The effect of price on pharmaceutical R and D

B.E. Journal of Economic Analysis and Policy

Volumn 9, Issue 1, 2009, Pages

  Civan, Abdulkadir ^a   Maloney, Michael T ^b  

^a FATIH UNIVERSITY   (Turkey)

^b CLEMSON UNIVERSITY   (United States)

Author keywords

Drug prices; Pharmaceutical R D

Indexed keywords

EID: 67649226587     PISSN: None     EISSN: 19351682     Source Type: Journal    
DOI: 10.2202/1935-1682.1977     Document Type: Article

References (15)

1. Abbott, T.A., & Vernon, J. (2005) "The Cost of US Pharmaceutical Price Reduction: A Financial Simulation Model of R&D," National Bureau Economic Research Working Paper No. 11114.
2. Civan, A., & Maloney, M.T. (2006) "The Determinants of Pharmaceutical Research and Development Investments," Contributions to Economic Analysis & Policy: Vol. 5, Issue 1, Article 28.
3. Danzon, P., & Kethcam, J. (2003) "Reference Pricing of Pharmaceuticals for Medicare:Evidence from Germany, The Netherlands and New Zealand," National Bureau of Economic Research Working Paper No. 10007, September (Cambridge MA: NBER).
4. Danzon, P., Wang, R., & Wang, L. (2003) "The Impact of Price Regulation on the Launch Delay of New Drugs- Evidence from Twenty-Five Major Markets in the 1990s," National Bureau of Economic Research Working Paper No. 9874, July (Cambridge MA: NBER).
5. DiMasi, J.A., Grabowski, H.G., & Vernon, J. (2004) "Costs and Returns by Therapeutic Category," Drug Information Journal: Vol. 38, Issue 3.
6. DiMasi, J.A., Hansen, R.W., & Grabowski, H.G. (2003) "The Price of Innovation: New Estimates of Drug Development Costs," Journal of Health Economics: Vol. 22, No. 2, pp. 151-185.
7. Giaccotto, C., Santerre, R.E., & Vernon, J. (2005) "Pricing and R&D Investment Behavior in the Pharmaceutical Industry," Journal of Law and Economics: Vol. XLVIII, pp. 195-214.
8. Golec, J., & Vernon, J. (2006) "European Pharmaceutical Price Regulation, Firm Profitability and R&D Spending," National Bureau Economic Research Working Paper No. 12676.
9. Grabowski, H.G., & Vernon, J.M. (1981) "The Determinants of R&D Expenditures," Drugs and health: AEI Press, Washington.
10. Grabowski, H.G., & Vernon, J.M. (2000) "John the Determinants of Pharmaceutical Research and Development Expenditures," Journal of Evolutionary Economics: Vol. 10, Issue 1-2, pp. 201-15, January.
11. Lichtenberg, F. (2005) "Pharmaceutical innovation and the burden of disease in developing and developed countries," Journal of Medicine and Philosophy: Vol. 30, Issue 6, December.
12. Lichtenberg, F. (2006) "Importation and Innovation," National Bureau Economic Research Working Paper No. 12539.
13. Mahlich, J.C., & Roediger-Schluga, T. (2006) "The Determinants of Pharmaceuical R&D Expenditures: Evidence from Japan," Review of Industrial Organization: Vol. 28, Issue 2, pp. 145-64, March.
14. Mathers, C.D., Bernard, C., Iburg, K., Inoue, M., Ma Fat, D., Shibuya, K., Stein, C., Tomijima, N. (2003) "The Global Burden of Disease in 2002: data sources, methods and results," World Health Organization, GPE Discussion Paper No. 54, 〈http://www.who.int/evidence〉.
15. Scherer, F.M. (2001) "The Link between Gross Profitability and Pharmaceutical R&D Spending," Health Affairs: Vol. 20.